Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study
Reproductive Toxicology Nov 23, 2017
Winter RW, et al. - Researchers used the National Danish Registries to examine the association between paternal Methotrexate (MTX) use three months before conception and adverse birth outcomes. They realized reassuring results regarding the effect of paternal use of MTX within 3 months before conception on birth outcomes of congenital anomalies (CAs), preterm birth and small for gestational age.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
